Study
MM120 Psychedelic Treatment Reduces Anxiety in Adults
Clinical trial finds psychedelic therapy may reduce anxiety, but older adults were underrepresented.
Summary
In plain language
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This clinical research demonstrates that MM120, a psychedelic compound, significantly reduces anxiety in adults. The study reports on treatment protocols, safety profiles, and sustained anxiety reduction following controlled administration of this investigational therapy.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
MM120 Psychedelic Treatment Reduces Anxiety in Adults
Published September 2025
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored March 23, 2026 using rubric v8_2026-03-10.
Assessment
The study is a well-conducted clinical trial published in a reputable journal, but it lacks detailed methodological transparency and has not been replicated. Its relevance to seniors is limited due to underrepresentation of older adults.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 6.7/10 | |
| Bias control | 6.7/10 | |
| Statistical methods | 5.0/10 | |
| Reporting completeness | 5.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 0.0/10 | |
| Journal Reliability | 10.0/10 |
Additional Notes
The study's focus on a novel treatment for anxiety is promising, but further replication and detailed methodological transparency are needed for stronger validation.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.